CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.

Cardiovascular Toxicology is a pivotal journal dedicated to advancing the understanding of the interplay between toxic substances and cardiovascular health. Published by HUMANA PRESS INC, this journal serves as a critical resource for researchers and professionals in the fields of cardiology, toxicology, and molecular biology. With an ISSN of 1530-7905 and an E-ISSN of 1559-0259, it has established itself as a key source of high-quality research since its inception in 2001, continuing to contribute valuable insights through 2024. The journal enjoys a robust reputation, evidenced by its Q2 ranking in both Cardiology and Cardiovascular Medicine and Toxicology, along with a Q3 ranking in Molecular Biology for 2023. With Scopus rankings placing it in the 80th percentile for Cardiology and 71st for Toxicology, Cardiovascular Toxicology attracts submissions that reflect cutting-edge research and innovative methodologies. Notably, the journal prioritizes stringent peer review and scholarly rigor, ensuring that published works significantly impact the understanding of cardiovascular responses to various toxic agents. Though not an open-access journal, its content remains highly sought after in a diverse scholarly community, making it indispensable for those dedicated to enhancing cardiovascular disease prevention, diagnosis, and treatment through toxicological insights.

Environmental Epigenetics, published by Oxford University Press, is a leading open access journal dedicated to advancing the understanding of the epigenetic mechanisms that underpin environmental influences on health and disease. With an ISSN of 2058-5888 and established as an open access platform since 2015, this journal serves as a vital resource for researchers in the fields of genetics, environmental science, and health, offering insights from multidisciplinary perspectives. The journal has gained notable recognition in the academic community, reflected by its impressive Scopus rankings and its classification in the second quartile (Q2) for Genetics and other related disciplines as of 2023. It aims to foster innovative research that bridges laboratory findings and real-world environmental issues, making it an indispensable tool for professionals and students pursuing knowledge at the intersection of genetics, environmental science, and public health. With its commitment to disseminating valuable research findings freely, Environmental Epigenetics stands out as an essential publication for those aiming to understand the significant impacts of environmental factors on genetic expression.

CHROMOSOMA is a prestigious journal dedicated to advancing the field of genetics, published by Springer in Germany. With an ISSN of 0009-5915 and an E-ISSN of 1432-0886, this journal has been a cornerstone in the publishing landscape since its inception in 1939, serving as a critical resource for researchers and professionals interested in the intricacies of chromosomal biology. Although it operates on a subscription basis, the journal's rigorous peer-review process ensures the dissemination of high-quality research findings. With a commendable Q2 ranking in both genetic and clinical genetics categories as of 2023, CHROMOSOMA aims to bridge theoretical concepts with practical applications in medicine and biology. Researchers will appreciate its relevance, as indicated by its Scopus ranks and integration of diverse topics ranging from molecular genetics to clinical implications. By fostering collaboration and knowledge-sharing among scholars, CHROMOSOMA continues to shape the future of genetic research.

Epigenetics Insights is an esteemed open-access journal published by SAGE Publications Ltd since 2018, dedicated to advancing the field of epigenetics and its implications in biochemistry and genetics. With an ISSN of 2516-8657, this journal has quickly established itself as a significant player in the academic landscape, positioned in the Q3 category for both Biochemistry and Genetics based on the 2023 rankings. Our mission is to provide a forum for high-quality research that delves into the complexities of epigenetic mechanisms, their biological significance, and their potential applications in medicine and biotechnology. By embracing the principles of open access, we ensure that cutting-edge findings are readily available to researchers, professionals, and students worldwide, thereby fostering knowledge sharing and collaborative advancements in this dynamic field. With articles indexed in Scopus and a growing citation impact, Epigenetics Insights aims to engage a diverse audience and inspire innovative research practices within the global scientific community.

Genetic Testing and Molecular Biomarkers, an esteemed journal published by MARY ANN LIEBERT, INC, serves as a pivotal platform for advancing the field of genetic research and its applications in medicine. Focused on the innovative intersections of genetics and biomarker discovery, this journal has consistently contributed meaningful insights since its inception in 2009, with its scope evolving through 2024. With an ISSN of 1945-0265 and an E-ISSN of 1945-0257, it offers both traditional and open access options to cater to a broad audience of researchers, professionals, and students. Despite its current classification in the Q4 and Q3 quartiles for Genetics (clinical) and Medicine (miscellaneous) respectively, the journal remains committed to publishing high-quality, peer-reviewed articles that push the boundaries of knowledge in the field. As the landscape of genomic medicine continues to expand, Genetic Testing and Molecular Biomarkers is positioned as a crucial resource for disseminating cutting-edge discoveries and fostering interdisciplinary collaboration.

RNA is a premier journal in the field of molecular biology, published by COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT. With an impressive impact factor reflected by its Q1 status in the Molecular Biology category, this journal has established itself as an essential resource for researchers and professionals dedicated to understanding the role of RNA in biological processes. Spanning over two decades of impactful research from 1995 to 2024, RNA covers a broad spectrum of topics, including RNA biology, gene regulation, and therapeutic innovations. Researchers can access its extensive array of original research articles, reviews, and commentary, making it a vital conduit for new discoveries and methodologies in the field. With its high ranking within Scopus at Rank #115/410 and a 72nd percentile ranking in the domain of Biochemistry, Genetics, and Molecular Biology, RNA continues to advance the understanding of RNA and its critical contributions to life sciences.

Human Genomics, published by BMC, is a leading open-access journal dedicated to advancing the field of genomics and its applications in health and disease. Since its inception in 2003, the journal has provided a vital platform for researchers to disseminate groundbreaking findings related to genetic research, contributing significantly to areas such as Drug Discovery, Genetics, Molecular Biology, and Molecular Medicine, as reflected in its Q1 and Q2 quartile rankings throughout 2023. With an ISSN of 1473-9542 and an E-ISSN of 1479-7364, Human Genomics not only delivers high-quality, peer-reviewed research but also ensures accessibility to a broader audience, empowering professionals, students, and academics to stay at the forefront of genomic science. Through its rigorous editorial standards and impactful publications, the journal fosters a collaborative environment for innovative research across the globe from its base in the United Kingdom. By promoting open access since its launch, Human Genomics continues to enhance the visibility and impact of genetic studies, making it an essential resource for anyone involved in the rapidly evolving field of human genomics.

GENES & DEVELOPMENT, published by COLD SPRING HARBOR LAB PRESS, stands as a premier journal in the fields of Developmental Biology and Genetics, boasting a remarkable impact factor that reflects its prestigious position in the academic community—ranking Q1 in both disciplines as of 2023. Since its inception in 1987, this journal has been at the forefront of disseminating cutting-edge research, effectively bridging the gap between laboratory breakthroughs and their applications in health and disease. Researchers and professionals rely on GENES & DEVELOPMENT for its rigorous peer-review process and its commitment to promoting innovative studies that unravel the complexities of gene functions and developmental processes. With Scopus rankings placing it in the top percentile among its peers, this journal serves as a vital resource for students and established scientists alike, aspiring to expand their knowledge and contribute to the ever-evolving landscape of genetic and developmental research.

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.